 | Up a level |
Studt, J-D; Alberio, L; Angelillo, Anne; Asmis, L M; Fontana, P; Korte, W; Mendez, A; Schmid, P; Stricker, H; Tsakiris, D A; Wuillemin, W A; Nagler, Michael (2017). Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels. Journal of thrombosis and haemostasis, 15(8), pp. 1576-1583. Wiley-Blackwell 10.1111/jth.13747
Bulla, O; Poncet, A; Alberio, L; Asmis, L M; Gähler, A; Graf, L; Nagler, Michael; Studt, J-D; Tsakiris, D A; Fontana, P (2017). Impact of a product-specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study. Haemophilia, 23(4), e335-e339. Wiley 10.1111/hae.13250
Asmis, L M; Alberio, L; Angelillo-Scherrer, A; Korte, W; Mendez, A; Reber, G; Seifert, B; Stricker, H; Tsakiris, D A; Wuillemin, W A (2011). Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories. Thrombosis research, 129(4), pp. 492-498. Amsterdam: Elsevier 10.1016/j.thromres.2011.06.031
Nendaz, M R; Chopard, P; Lovis, C; Kucher, N; Asmis, L M; Dörffler, J; Spirk, D; Bounameaux, H (2010). Adequacy of venous thromboprophylaxis in acutely ill medical patients (IMPART): multisite comparison of different clinical decision support systems. Journal of thrombosis and haemostasis, 8(6), pp. 1230-4. Oxford: Wiley-Blackwell 10.1111/j.1538-7836.2010.03817.x
